Vybor taktiki lecheniya u patsientov s neudovletvoritel'noy kompensatsiey sakharnogo diabeta 2 tipa: vozmozhnosti naznacheniya mimetika inkretinov eksenatida (na primere klinicheskogo sluchaya)
https://doi.org/10.14341/2072-0351-5598
Abstract
References
1. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study Group. Diabetes 1995; 44:1249-1258.
2. Turner RC, Cull CA, Frighi V, Holman RR; UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: prospective requirement for multiple therapies (UKPDS 49). JAMA 1999; 281:2005-2012.
3. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes care 2008; 31(suppl 1): S12-S54.
4. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963-1972.
5. Rodbard HW, Blonde L, Braithwaite SS et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007; 13(suppl 1): 3-68.
6. Halperin F, Ingelfinger JR, McMahon GT. Management of type 2 diabetes - polling results. Interactive at www.nejm.ogr.
7. Aljabri K, Kozak SE, Thompson DM. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. Am J Med 2004; 116: 230-235.
8. Schwarts S, Sievers R, Strange P, Lyness WH, Hollander P, INS-2061 Study Team. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis. Diabetes Care 2003; 26: 2238-43.
9. Rosenstock J, Sugimoto D, Strange P et al. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naп ve patients. Diabetes Care 2006; 29: 554-559.
10. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355:2427-2443.
11. Dorkhan M, Magnusson M, Frid A et al. Glycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetes. J Intern Med 2006; 260: 125-133.
12. Dormandy JA, Charbonnel B, Eckland EJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes: a randomized trial of pioglitazone. The PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events). Lancet 2005;366:1279-1289.
13. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a metaanalysis of randomized trials. JAMA 2007; 298: 1180-1188.
14. Schwarts AV, Sellmeyer DE, Vittinghoff E et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006; 91: 3349-54.
15. Rury R. Holman, Kerensa I. Thorne, Andrew J. Farmer, Melanie J. Davies, Joanne F. Keenan, Sanjoy Paul, Jonathan C. Levy, for the 4-T Study Group Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes N Eng J Med 2007; 357: 1716-30.
16. Mortensen K, Christensen LL, Holst JJ, Orskov C. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Rept 2003; 114:189-96.
17. Nauck MA, Heimesaat MM, Orskov C et al. Preserved incretin activity of glucagon-like peptide-1 (7-36 amide) but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91: 301-7.
18. Holst JJ. GLP-1 receptor agonists for the treatment of diabetes. Int Diabetes Monitor 2005; 17(6):11-18.
19. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes. Systemic review and meta-analysis. JAMA 2007; 298:194-206.
20. Kendall DM, Riddle MC, Rosenstock J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28(5):1083-91.
21. Heine RJ, Van Gaal LF, Johns D, Mihm M, et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005; 143(8):559-569.
22. Nauck MA, Duran S, Kim D, Johns D et al. A comparison of a twicedaily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007; 50:259-267.
23. Maggio CA, Pi-Sunyer FX. Obesity and type 2 diabetes. Endocrinology and Metabolism Clinics of North America 2003; 32 :805-822.
24. Blonde L, Klein EJ, Han J et al. Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 patients with type 2 diabetes. Diabetes Obes Metab 2006; 8:436-47.
25. Degn KB, Brock B, Juhl CB et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and couterregulation during hypoglycemia. Diabetes 2004; 53(9): 2397-403.
26. DeFronzo R, Ratner R, Han J et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28(5): 1092-100.
27. Buse J, Henry R, Han J et al. Effests of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27(11): 2628-35.
28. Van Gaal LF, Gutkin SW, Nauck MA. Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagons-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control? European Journal of Endocrinology 2008; 158:773-784.
Review
For citations:
Vikulova O.K. Vybor taktiki lecheniya u patsientov s neudovletvoritel'noy kompensatsiey sakharnogo diabeta 2 tipa: vozmozhnosti naznacheniya mimetika inkretinov eksenatida (na primere klinicheskogo sluchaya). Diabetes mellitus. 2008;11(4):84-88. https://doi.org/10.14341/2072-0351-5598
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
